Third German Hospital Selects IntraOp Medical Corporation’s Mobetron

IntraOp Medical Corporation (OTC:IOPD.PK) (News) today announced that Marien Hospital Düsseldorf GmbH became the third German hospital and the fifteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

"There is an increasing interest by German hospitals to acquire IOERT capability,” says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor. "The clinical data showing the effectiveness of IOERT for breast cancer compared to the conventional treatment for breast cancer is very convincing, and German hospitals are all looking to provide their patients the best breast cancer treatment possible—and that is IOERT.”

Marien Hospital Düsseldorf GmbH in the city of Dusseldorf is one of the most important treatment centers in North Rhine-Westphalia (NRW), very famous for its breast cancer unit. Doctor Martin Meyer, CEO of Marien Hospital, says, "The acquisition of the Mobetron will help increase the standard of care in our Hospital and will allow Professor Audretsch to implement and increase the positive results we are achieving in the cure of breast cancer. Mobetron is for us a strategic investment for the future and for the development of our Hospital.”

Professor Werner Audretsch, one of the most famous breast surgeons in Europe, stated that, "The Mobetron will help us to shorten the treatment time, to raise the bar of quality in Oncoplastic Surgery and allow us to obtain better results in terms of cosmesis, quality of surgery, increase of success against breast cancer and of course, and most important, will bring to our patients a brighter view and hope of their future.”

Professor Dr. med. Karl Axel Hartmann, radiation oncologist, adds that, "The start of our IOERT program with the Mobetron will be a big boost both for our Institution and the standard of care for breast cancer in our region. I am sure that the collaegues of our surgery department will develop other treatment options to be added to the breast cancer programme. The Mobetron is a true linear accelerator which will make it easy to expand our IOERT program to other cancer sites in the future.”

"We are very excited to add Marien Hospital to growing list of world class cancer centers using the Mobetron. IOERT for breast cancer is becoming very prevalent throughout Europe,” said John Powers, President and CEO of IntraOp Medical. The Mobetron uses electron radiation, IOERT, which is the fastest, safest, most versatile, and precise way to deliver radiation therapy. The Mobetron delivers concentrated electron beam radiation directly to the exposed tumor bed to an exact depth during cancer surgery.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program. For more information email jpowers@intraopmedical.com or call 408-636-1020 x128.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.